biostudies-literatureDassau EItalian Ministero dell’Università e della Ricerca ScientificaNCATS NIH HHSNational Institute of Diabetes and Digestive and Kidney DiseasesNIDDK NIH HHSUrdang Family FoundationNational Center for Advancing Translational Science1719-1726https://www.ebi.ac.uk/biostudies/studies/S-EPMC5711334biostudies-literatureUnknown40(12)<h4>Objective</h4>Artificial pancreas (AP) systems are best positioned for optimal treatment of type 1 diabetes (T1D) and are currently being tested in outpatient clinical trials. Our consortium developed and tested a novel adaptive AP in an outpatient, single-arm, uncontrolled multicenter clinical trial lasting 12 weeks.<h4>Research design and methods</h4>Thirty adults with T1D completed a continuous glucose monitor (CGM)-augmented 1-week sensor-augmented pump (SAP) period. After the AP was started, basal insulin delivery settings used by the AP for initialization were adapted weekly, and carbohydrate ratios were adapted every 4 weeks by an algorithm running on a cloud-based server, with automatic data upload from devices. Adaptations were reviewed by expert study clinicians and patients.Diabetes careTwelve-Week 24/7 Ambulatory Artificial Pancreas With Weekly Adaptation of Insulin Delivery Settings: Effect on Hemoglobin A_1c and Hypoglycemia.PMC5711334UL1-TR-000135Progetto di Ateneo dell’Università di Padova 2014UL1 TR000135DP3 DK094331DP3-DK-094331Bevier WCKudva YCAnderson SHinshaw LDadlani VBasu ADalla Man CPatek SDassau ESchiavon MHughes JChurch MMGondhalekar RDoyle FJHuyett LMBrown SALv DPinsker JEDasanayake IMcCrady-Spitzer SKCarter RECobelli CSchertz EEmory EBradley PKLaguna Sanz AJKovatchev BJean TfalseTwelve-Week 24/7 Ambulatory Artificial Pancreas With Weekly Adaptation of Insulin Delivery Settings: Effect on Hemoglobin A_1c and Hypoglycemia.<h4>Objective</h4>Artificial pancreas (AP) systems are best positioned for optimal treatment of type 1 diabetes (T1D) and are currently being tested in outpatient clinical trials. Our consortium developed and tested a novel adaptive AP in an outpatient, single-arm, uncontrolled multicenter clinical trial lasting 12 weeks.<h4>Research design and methods</h4>Thirty adults with T1D completed a continuous glucose monitor (CGM)-augmented 1-week sensor-augmented pump (SAP) period. After the AP was started, basal insulin delivery settings used by the AP for initialization were adapted weekly, and carbohydrate ratios were adapted every 4 weeks by an algorithm running on a cloud-based server, with automatic data upload from devices. Adaptations were reviewed by expert study clinicians and patients.2017-01-01T00:00:00Z2017 Dec2026-05-02T19:29:52.328Z2019-03-27T00:09:16ZS-EPMC57113342903038310.2337/dc17-1188